Today: 19 April 2026
DroneShield stock rebounds 8.6% after Friday sell-off — what ASX:DRO investors watch next
9 February 2026
1 min read

DroneShield stock rebounds 8.6% after Friday sell-off — what ASX:DRO investors watch next

Sydney, Feb 9, 2026, 17:43 (AEDT) — The session has ended.

Shares of DroneShield Limited (DRO.AX) jumped 8.6% Monday, settling at A$3.15. The stock moved in a range from A$3.10 to A$3.32 during the session. It finished at A$2.90 on Friday, and despite the day’s rally, remains roughly 53% under its 52-week peak of A$6.705.

Australian stocks snapped back hard, the S&P/ASX 200 climbing 1.85% following Friday’s bruising session. “If you look at the sectors that are doing well, it’s the ones which got absolutely pulverised on Friday,” IG market analyst Tony Sycamore said to AAP. Dip-buying was broad. CommBank

The stakes are up for DroneShield as its shares, which have shown high-beta tendencies—often swinging harder than the broader market—face the coming gauntlet of earnings season. This week, three of the “Big Four” Australian banks will deliver results. Healthcare and mining names are also set to report. mint

DroneShield, active in both Australia and the U.S., provides technology designed to detect and stop drones. According to the company, its counter-UAS lineup relies on radio-frequency sensing, sensor fusion, and electronic warfare — a catch-all for jamming and other tactics that disrupt signals.

Friday’s slump was brutal. The Australian share market lost close to $70 billion—its sharpest one-day fall in nearly a year, according to ABC News. “Panic is spreading,” an analyst told the network. ABC News

Potential share supply remains on investors’ radar. In a Feb. 6 filing, the company disclosed it’s seeking quotation for 370,000 fully paid ordinary shares at A$0.326 apiece—these shares stem from performance rights that vested back in January and carry no restrictions.

Asian equities climbed on Monday, chip stocks jumping, as steadier overnight cues set the stage. Investors kept an eye on the possibility the U.S. Federal Reserve could cut rates by June, according to Reuters.

Still, DroneShield can be a wild ride if risk sentiment shifts, or if contracts don’t land on schedule. Back in November, Reuters highlighted how the stock’s surge stumbled—executive share sales, governance concerns, a misstep in contract disclosure, and leadership shakeups all weighed.

Late February is the key mark for this stock. DroneShield’s annual and preliminary reports drop on Feb. 24, according to a market schedule. Eyes will be on headline revenue, but cash flow, contract conversion, and when deliveries actually happen are set to draw just as much investor scrutiny.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Air Transat’s Brazil bet: Rio flights take off as 50 new airline routes start in February 2026
Previous Story

Air Transat’s Brazil bet: Rio flights take off as 50 new airline routes start in February 2026

OCBC share price rises as DBS profit miss sharpens focus on Singapore bank earnings
Next Story

OCBC share price rises as DBS profit miss sharpens focus on Singapore bank earnings

Go toTop